THREE-YEAR RESULTS FROM THE EVOLVE II RANDOMIZED TRIAL: LATE CLINICAL OUTCOMES WITH BIORESORBABLE COMPARED TO PERMANENT POLYMER EVEROLIMUS-ELUTING
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY(2017)
Abstract
Background: Although drug-eluting stents reduce cardiac events compared with bare metal stents, permanent polymers may result in chronic inflammation, delayed arterial healing and increased risk of late cardiac events. Resorbable polymers may reduce inflammation and mitigate late/ very-late adverse
MoreTranslated text
Key words
evolve ii randomized trial,late clinical outcomes,clinical outcomes,randomized trial,three-year,everolimus-eluting
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined